NDAORALCAPSULE
Approved
Jun 2018
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
7/8 — Comprehensive
BRAFTOVI (encorafenib) by Pfizer is v600e, as well as wild-type braf and craf in in vitro cell-free assays with ic 50 values of 0. First approved in 2018.
Drug data last refreshed 13h ago · AI intelligence enriched 17h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BRAFTOVI (encorafenib) is an oral BRAF kinase inhibitor approved in 2018 that targets tumors with BRAF V600 mutations, including melanoma, colorectal cancer, and non-small cell lung cancer. It works by suppressing the RAF/MEK/ERK pathway, blocking constitutively activated BRAF kinases that drive tumor growth. The drug is most effective when combined with MEK inhibitors like binimetinib or EGFR-targeting agents like cetuximab to overcome resistance mechanisms.
$0.087BPart D
Peak6.9 years to LOEProduct is at peak commercial maturity with stable Part D spending, supporting established brand and medical teams.
Mechanism of Action
V600E, as well as wild-type BRAF and CRAF in in vitro cell-free assays with IC 50 values of 0.35, 0.47, and 0.3 nM, respectively. Mutations in the BRAF gene, such as BRAF V600E, can result in constitutively activated BRAF kinases that may stimulate tumor cell growth. Encorafenib was also able to…
Indications
Worked on BRAFTOVI at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.